Does the media prefer RLAY or TBPH?

In the previous week, Relay Therapeutics had 13 more articles in the media than Theravance Biopharma. MarketBeat recorded 16 mentions for Relay Therapeutics and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Relay Therapeutics' score of 0.79 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Theravance Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, TBPH or TLX?

Theravance Biopharma has higher earnings, but lower revenue than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Theravance Biopharma $107.46M 8.09 $105.89M $2.20 7.66 Telix Pharmaceuticals $803.79M 4.18 -$7.12M N/A N/A

Does the media favor TBPH or TLX?

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Telix Pharmaceuticals and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Telix Pharmaceuticals' score of 0.45 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Telix Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ALMS or TBPH?

Theravance Biopharma has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $8.40M 428.67 -$243.32M -$1.98 N/A Theravance Biopharma $107.46M 8.09 $105.89M $2.20 7.66

Does the media refer more to ALMS or TBPH?

In the previous week, Alumis had 8 more articles in the media than Theravance Biopharma. MarketBeat recorded 11 mentions for Alumis and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Alumis' score of 1.57 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Theravance Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor RCUS or TBPH?

In the previous week, Arcus Biosciences had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 6 mentions for Arcus Biosciences and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Arcus Biosciences' score of 0.27 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to GPCR or TBPH?

In the previous week, Structure Therapeutics had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Structure Therapeutics and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Structure Therapeutics' score of 1.15 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Theravance Biopharma (TBPH) Competitors

$16.86 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$16.86 +0.00 (+0.03%)

As of 07/31/2026 05:21 PM Eastern

Compare

TBPH vs. RLAY, TLX, ALMS, RCUS, and GPCR

Should you buy Theravance Biopharma stock or one of its competitors? MarketBeat compares Theravance Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Theravance Biopharma include Relay Therapeutics (RLAY), Telix Pharmaceuticals (TLX), Alumis (ALMS), Arcus Biosciences (RCUS), and Structure Therapeutics (GPCR).

How does Theravance Biopharma compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Theravance Biopharma has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.68M	337.91	-$276.48M	-$1.57	N/A
Theravance Biopharma	$107.46M	8.09	$105.89M	$2.20	7.66

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Theravance Biopharma has a net margin of 104.34% compared to Relay Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Theravance Biopharma	104.34%	18.84%	10.94%

Relay Therapeutics currently has a consensus target price of $24.92, suggesting a potential upside of 32.32%. Theravance Biopharma has a consensus target price of $19.40, suggesting a potential upside of 15.07%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Relay Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Relay Therapeutics had 13 more articles in the media than Theravance Biopharma. MarketBeat recorded 16 mentions for Relay Therapeutics and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Relay Therapeutics' score of 0.79 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Theravance Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Relay Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Summary

Theravance Biopharma beats Relay Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to Telix Pharmaceuticals?

Theravance Biopharma (NASDAQ:TBPH) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Telix Pharmaceuticals and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Telix Pharmaceuticals' score of 0.45 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Telix Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Theravance Biopharma has a net margin of 104.34% compared to Telix Pharmaceuticals' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Telix Pharmaceuticals	N/A	N/A	N/A

Theravance Biopharma has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

99.1% of Theravance Biopharma shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Theravance Biopharma has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.09	$105.89M	$2.20	7.66
Telix Pharmaceuticals	$803.79M	4.18	-$7.12M	N/A	N/A

Theravance Biopharma presently has a consensus target price of $19.40, indicating a potential upside of 15.07%. Telix Pharmaceuticals has a consensus target price of $20.40, indicating a potential upside of 106.27%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

Theravance Biopharma beats Telix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Theravance Biopharma compare to Alumis?

Alumis (NASDAQ:ALMS) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Alumis has a beta of -0.73, meaning that its stock price is 173% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

99.1% of Theravance Biopharma shares are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alumis presently has a consensus price target of $40.30, indicating a potential upside of 42.65%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 15.07%. Given Alumis' stronger consensus rating and higher probable upside, research analysts clearly believe Alumis is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Alumis had 8 more articles in the media than Theravance Biopharma. MarketBeat recorded 11 mentions for Alumis and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Alumis' score of 1.57 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Theravance Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Theravance Biopharma has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$8.40M	428.67	-$243.32M	-$1.98	N/A
Theravance Biopharma	$107.46M	8.09	$105.89M	$2.20	7.66

Theravance Biopharma has a net margin of 104.34% compared to Alumis' net margin of -2,825.70%. Theravance Biopharma's return on equity of 18.84% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Theravance Biopharma	104.34%	18.84%	10.94%

Summary

Theravance Biopharma beats Alumis on 10 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Theravance Biopharma has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$236M	15.02	-$353M	-$3.18	N/A
Theravance Biopharma	$107.46M	8.09	$105.89M	$2.20	7.66

Theravance Biopharma has a net margin of 104.34% compared to Arcus Biosciences' net margin of -156.36%. Theravance Biopharma's return on equity of 18.84% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Theravance Biopharma	104.34%	18.84%	10.94%

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arcus Biosciences presently has a consensus target price of $36.40, suggesting a potential upside of 29.18%. Theravance Biopharma has a consensus target price of $19.40, suggesting a potential upside of 15.07%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Arcus Biosciences had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 6 mentions for Arcus Biosciences and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Arcus Biosciences' score of 0.27 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Theravance Biopharma beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Theravance Biopharma has a net margin of 104.34% compared to Structure Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Theravance Biopharma	104.34%	18.84%	10.94%

Theravance Biopharma has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Theravance Biopharma	$107.46M	8.09	$105.89M	$2.20	7.66

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Structure Therapeutics has a beta of -1.43, suggesting that its share price is 243% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Structure Therapeutics presently has a consensus price target of $110.55, suggesting a potential upside of 130.11%. Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 15.07%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Structure Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Structure Therapeutics had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Structure Therapeutics and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.61 beat Structure Therapeutics' score of 1.15 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Theravance Biopharma beats Structure Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TBPH vs. The Competition

Export

Metric	Theravance Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$869.13M	$11.72B	$6.85B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	7.66	799.05	282.28	24.66
Price / Sales	8.09	751.77	563.21	75.35
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	2.88	10.27	10.96	6.07
Net Income	$105.89M	$2.82B	$3.49B	$347.99M
7 Day Performance	N/A	-0.18%	-0.63%	-0.44%
1 Month Performance	-0.41%	-4.02%	-5.23%	-4.81%
1 Year Performance	54.68%	156.06%	62.07%	18.61%

Theravance Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TBPH Theravance Biopharma	2.7485 of 5 stars	$16.86 flat	$19.40 +15.1%	+54.7%	$869.13M	$107.46M	7.66	110	News Coverage Positive News
RLAY Relay Therapeutics	3.0108 of 5 stars	$18.16 -2.6%	$24.92 +37.2%	+460.4%	$3.48B	$10.68M	N/A	330	Trending News Upcoming Earnings Gap Up
TLX Telix Pharmaceuticals	4.1118 of 5 stars	$10.14 +1.6%	$20.40 +101.2%	-24.2%	$3.45B	$803.79M	N/A	1,184
ALMS Alumis	4.336 of 5 stars	$26.95 -0.5%	$40.30 +49.6%	+584.0%	$3.43B	$8.40M	N/A	N/A	Positive News Gap Up
RCUS Arcus Biosciences	2.7999 of 5 stars	$26.84 -3.6%	$36.40 +35.6%	+207.6%	$3.36B	$236M	N/A	500	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TBPH) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Competitors

TBPH vs. RLAY, TLX, ALMS, RCUS, and GPCR

How does Theravance Biopharma compare to Relay Therapeutics?

Summary

How does Theravance Biopharma compare to Telix Pharmaceuticals?

Summary

How does Theravance Biopharma compare to Alumis?

Summary

How does Theravance Biopharma compare to Arcus Biosciences?

Summary

How does Theravance Biopharma compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Theravance Biopharma (TBPH) Competitors

TBPH vs. RLAY, TLX, ALMS, RCUS, and GPCR

How does Theravance Biopharma compare to Relay Therapeutics?

Which has better valuation & earnings, RLAY or TBPH?

Do institutionals and insiders hold more shares of RLAY or TBPH?

Is RLAY or TBPH more profitable?

Do analysts recommend RLAY or TBPH?

Does the media prefer RLAY or TBPH?

Which has more risk & volatility, RLAY or TBPH?

Summary

How does Theravance Biopharma compare to Telix Pharmaceuticals?

Does the media favor TBPH or TLX?

Is TBPH or TLX more profitable?

Which has more risk and volatility, TBPH or TLX?

Do institutionals and insiders believe in TBPH or TLX?

Which has higher valuation and earnings, TBPH or TLX?

Do analysts prefer TBPH or TLX?

Summary

How does Theravance Biopharma compare to Alumis?

Which has more volatility and risk, ALMS or TBPH?

Do institutionals and insiders believe in ALMS or TBPH?

Do analysts prefer ALMS or TBPH?

Does the media refer more to ALMS or TBPH?

Which has higher earnings and valuation, ALMS or TBPH?

Is ALMS or TBPH more profitable?

Summary

How does Theravance Biopharma compare to Arcus Biosciences?

Which has more volatility & risk, RCUS or TBPH?

Which has higher valuation & earnings, RCUS or TBPH?

Is RCUS or TBPH more profitable?

Do insiders & institutionals have more ownership in RCUS or TBPH?

Do analysts prefer RCUS or TBPH?

Does the media favor RCUS or TBPH?

Summary

How does Theravance Biopharma compare to Structure Therapeutics?

Is GPCR or TBPH more profitable?

Which has stronger valuation and earnings, GPCR or TBPH?

Do institutionals & insiders have more ownership in GPCR or TBPH?

Which has more risk & volatility, GPCR or TBPH?

Do analysts rate GPCR or TBPH?

Does the media refer more to GPCR or TBPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools